- Home
- EQ vs ORKT Comparison
EQ vs ORKT Comparison
Compare EQ & ORKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- ORKT
- Stock Information
- Founded
- EQ 2017
- ORKT 2003
- Country
- EQ United States
- ORKT Singapore
- Employees
- EQ N/A
- ORKT N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- ORKT
- Sector
- EQ Health Care
- ORKT
- Exchange
- EQ Nasdaq
- ORKT NYSE
- Market Cap
- EQ 31.1M
- ORKT 34.7M
- IPO Year
- EQ 2018
- ORKT 2024
- Fundamental
- Price
- EQ $0.88
- ORKT $1.10
- Analyst Decision
- EQ Buy
- ORKT Strong Buy
- Analyst Count
- EQ 2
- ORKT 1
- Target Price
- EQ $5.00
- ORKT $5.00
- AVG Volume (30 Days)
- EQ 2.2M
- ORKT 5.4M
- Earning Date
- EQ 03-24-2025
- ORKT 10-16-2024
- Dividend Yield
- EQ N/A
- ORKT N/A
- EPS Growth
- EQ N/A
- ORKT N/A
- EPS
- EQ N/A
- ORKT N/A
- Revenue
- EQ $45,914,000.00
- ORKT $3,904,592.00
- Revenue This Year
- EQ $4.77
- ORKT N/A
- Revenue Next Year
- EQ N/A
- ORKT $39.99
- P/E Ratio
- EQ N/A
- ORKT N/A
- Revenue Growth
- EQ 7.70
- ORKT N/A
- 52 Week Low
- EQ $0.49
- ORKT $0.62
- 52 Week High
- EQ $3.25
- ORKT $8.00
- Technical
- Relative Strength Index (RSI)
- EQ 58.42
- ORKT N/A
- Support Level
- EQ $0.85
- ORKT N/A
- Resistance Level
- EQ $0.98
- ORKT N/A
- Average True Range (ATR)
- EQ 0.10
- ORKT 0.00
- MACD
- EQ 0.01
- ORKT 0.00
- Stochastic Oscillator
- EQ 62.50
- ORKT 0.00
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.